+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 2Years +
All Genders
ID07285005

Phase 3 Study of KP-001 Compared With Placebo in Patients Aged 2 Years and Older With Common Venous Malformations, Lymphatic Malformations, or KTSCLOVES Syndrome

Led by Kaken Pharmaceutical · Updated on 2026-09-21

150

Participants Needed

5

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of KP-001 compared with a placebo in patients aged 2 years and older who have common venous malformations, common lymphatic malformations, or Klippel-Trenaunay Syndrome KTSCLOVES Syndrome. This phase 3, double-blind, randomized, placebo-controlled study will be conducted at multiple centers across North America, Canada, Taiwan, and South Korea. An independent data monitoring committee will review interim results to decide whether to continue or modify the study. Participants will undergo a screening period up to 42 days before receiving any study treatment. During the first 24 weeks, patients will receive KP-001 100 mg or a lower dose based on body weight or placebo once daily after breakfast in a double-blind manner. After this period, all patients will enter a 28-week open-label extension phase where they will receive KP-001 until week 52. Following treatment, a follow-up visit will occur 30 days after the last dose, and there will be assessments at discontinuation if a participant leaves the study early. Throughout the study, participants will have their vital signs and safety labs monitored regularly, including blood tests and urinalysis. The main outcome measured is the change in volume of target lesions using MRI before treatment and at 24 weeks. Additional assessments include patient-reported symptom scores, pain inventories, global impression scales, quality of life measures, and safety evaluations up to 52 weeks. Researchers will also monitor adverse events and clinical events related to vascular malformations during this time.

CONDITIONS

Brief Title

A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome

Research Team

S

Sr. Clinical Trial Manager, Clinical Operations

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here